MMP-2 plasma concentrations were significantly augmented in the LAC group (all lung cancer patients examined) when compared to healthy subjects (266.7 ± 6.3 ng/ml and 133.2 ± 4.2 ng/ml, respectively; p < 0.0001) (Figure 1(a)). This evidence concerns the gene MMP2 and lung carcinoma.